Home>Products>Biosimilar reference antibodies

Biosimilar reference antibodies

To develop a superior biologic drug, it is important to synthesize a benchmark reference antibody. The reference antibody can greatly facilitate the downstream development. It can help identify critical cell lines, reagents, performance characteristics, etc.


DIMA Biotechnology LTD utilizes HEK293 mammalian cell secretion expression system and we implemented a strict quality control process, including purity testing, target binding verification, etc.

Product targets:

CD47 IL6 SARS-CoV CD30 CD20 TNFRSF10B
CS1 TIM3 CD138 CD40 TIGIT TweakR
CD123 PDL1 CD33 MSLN TIGIT CD22
CD38 B7-H3 CD27 CTLA4 BCMA TIGIT
CD70 SARS-CoV-2 EPHA3 Trop2 EGFR AXL
PD-1 ICOS

Free trial available! Click to apply!

  • Strict Quality Control
  • :

Active protein detection

Figure 1. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human PD1, mFc-His tagged protein (PME100025) can bind Anti-PD-1 Neutralizing antibody in a linear range of 0.24-6.49 ng/ml.

Comparison of flow functional detection

Figure 2. HEK293 cell line transfected with irrelevant protein (B) and human PD1(A) were surface stained with anti-PD1 neutralizing antibody 1μg/ml (pembrolizumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.



0.0742s